Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

      Background & Aims

      Strategies to eradicate Helicobacter pylori infection could be improved by suppressing acid and extending the duration of therapy (optimization). We compared the efficacy of 2 different optimized nonbismuth quadruple regimens in areas of high resistance to antimicrobial agents.


      We performed a prospective noninferiority multicenter trial in which 343 consecutive individuals with H pylori infection were assigned randomly to groups given hybrid therapy (40 mg omeprazole and 1 g amoxicillin, twice daily for 14 days; 500 mg clarithromycin and 500 mg nitroimidazole were added, twice daily for the final 7 days) or concomitant therapy (same 4 drugs taken concurrently, twice daily for 14 days). We assessed bacterial resistance to these drugs in a subset of patients using the E-test. Efficacy, side effects, and compliance were determined.


      In per-protocol analysis, rates of eradication for hybrid and concomitant therapies were 92% (95% confidence interval [CI], 87%−95%) and 96.1% (95% CI, 93%–99%), respectively (P = .07). In intention-to-treat analysis, rates were 90% (95% CI, 86%−93%) and 91.7% (95% CI, 87%–95%), respectively (P = .35). Almost all patients (95.5%) were fully compliant; 23.5% of patients had H pylori strains that were resistant to clarithromycin (Italy, 26%; Spain, 19.5%), 33% were resistant to metronidazole (Italy, 33%; Spain, 34%), and 8.8% were resistant to both drugs (Italy, 7.1%; Spain, 11.5%). Side effects (only mild) were reported in 51.5% of patients (47% hybrid vs 56% concomitant; P = .06). Compliance greater than 80% was the only significant predictor of eradication (odds ratio, 12.5; 95% CI, 3.1−52; P = .001). Significantly more patients were compliant with hybrid therapy (98.8%) than concomitant therapy (95.2%; P = .05).


      Optimized nonbismuth quadruple hybrid and concomitant therapies cured more than 90% of patients with H pylori infections in areas of high clarithromycin and metronidazole resistance. number NCT01464060.


      Abbreviations used in this paper:

      ITT (intention-to-treat), PP (per protocol), PPI (proton pump inhibitor)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.
        • et al.
        Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.
        Gut. 2007; 56: 772-781
        • Chey W.D.
        • Wong B.C.
        American College of Gastroenterology Guideline on the management of Helicobacter pylori infection.
        Am J Gastroenterol. 2007; 102: 1808-1825
        • Megraud F.
        • Coenen S.
        • Versporten A.
        • et al.
        Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.
        Gut. 2013; 62: 34-42
        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.A.
        • et al.
        Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report.
        Gut. 2012; 61: 646-664
        • Fischbach L.
        • Evans E.L.
        Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.
        Aliment Pharmacol Ther. 2007; 26: 343-357
        • Malfertheiner P.
        • Bazzoli F.
        • Delchier J.C.
        • et al.
        Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
        Lancet. 2011; 377: 905-913
        • Jafri N.S.
        • Hornung C.A.
        • Howden C.W.
        Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment.
        Ann Intern Med. 2008; 148: 923-931
        • Tong J.L.
        • Ran Z.H.
        • Shen J.
        • et al.
        Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.
        J Clin Pharm Ther. 2009; 34: 41-53
        • Gatta L.
        • Vakil N.
        • Leandro G.
        • et al.
        Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
        Am J Gastroenterol. 2009; 104: 3069-3079
        • Essa A.S.
        • Kramer J.R.
        • Graham D.Y.
        • et al.
        Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication.
        Helicobacter. 2009; 14: 109-118
        • Gisbert J.
        • Nyssen O.P.
        • McNicholl A.G.
        • et al.
        Meta-analysis of sequential versus standard triple therapy.
        Helicobacter. 2011; 16: 132
        • Gisbert J.P.
        • Calvet X.
        Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.
        Clin Exp Gastroenterol. 2012; 5: 23-34
        • Molina-Infante J.
        • Perez-Gallardo B.
        • Fernandez-Bermejo M.
        • et al.
        Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
        Aliment Pharmacol Ther. 2010; 31: 1077-1084
        • Romano M.
        • Cuomo A.
        • Gravina A.G.
        • et al.
        Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
        Gut. 2010; 59: 1465-1470
        • Molina-Infante J.
        • Pazos-Pacheco C.
        • Vinagre-Rodriguez G.
        • et al.
        Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible H. pylori and versus sequential therapy for clarithromycin-resistant strains.
        Helicobacter. 2012; 17: 269-276
        • Hsu P.I.
        • Wu D.C.
        • Wu Y.C.
        • et al.
        Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
        Helicobacter. 2011; 16: 139-145
        • Gisbert J.P.
        • Marin A.C.
        • Molina-Infante J.
        Second-line rescue triple therapy with levofloxacin after failure of quadruple non-bismuth “sequential” or “concomitant” treatment.
        Gastroenterology. 2012; 142: S-482
        • Federico A.
        • Nardone G.
        • Gravina A.G.
        • et al.
        Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
        Gastroenterology. 2012; 143: 55-61
        • Glupczynski Y.
        • Megraud F.
        • Lopez-Brea M.
        • et al.
        European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.
        Eur J Clin Microbiol Infect Dis. 2001; 20: 820-823
        • Graham D.Y.
        • Fischbach L.
        Helicobacter pylori treatment in the era of increasing antibiotic resistance.
        Gut. 2010; 59: 1143-1153
        • D’Agostino R.B.
        • Massaro J.M.
        • Sullivan L.M.
        Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics.
        Stat Med. 2003; 22: 169-186
      1. Guidance for industry—non-inferiority clinical trials. Available at: Accessed Dec 1, 2012.

        • Wu D.C.
        • Hsu P.I.
        • Wu J.Y.
        • et al.
        Sequential and concomitant therapy with 4 drugs are equally effective for H. pylori infection.
        Clin Gastroenterol Hepatol. 2010; 8: 36-41
        • Huang Y.K.
        • Wu M.C.
        • Wang S.S.
        • et al.
        Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
        J Dig Dis. 2012; 13: 232-238
        • Liou J.M.
        • Chen C.C.
        • Chen M.J.
        • et al.
        Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
        Lancet. 2013; 381: 205-213
        • McNicholl A.G.
        • Marín A.C.
        • Molina-Infante J.
        • et al.
        Phase IV, prospective, randomized and comparative study between sequential and concomitant therapy for Helicobacter pylori eradication in routine clinical practice.
        Gut. 2013; (May 11 [Epub ahead of press])
        • Sardarian H.
        • Fakheri H.
        • Hosseini V.
        • et al.
        Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
        Helicobacter. 2013; 18: 129-134
        • Wu J.Y.
        • Hsu P.I.
        • Wu D.C.
        • et al.
        Optimal duration to maintain greater than 95% eradication rate in hybrid therapy for H. pylori.
        Gastroenterology. 2012; : S-484
        • Vaira D.
        • Zullo A.
        • Hassan C.
        • et al.
        Sequential therapy for Helicobacter pylori eradication: the time is now.
        Ther Adv Gastroenterol. 2009; 2: 317-322
        • Chuah S.K.
        • Tai W.C.
        • Hsu P.I.
        • et al.
        The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment–a pilot study.
        Helicobacter. 2012; 17: 374-381
        • Working Party of the European Helicobacter pylori Study Group
        Technical annex: tests used to assess Helicobacter pylori infection.
        Gut. 1997; 41: S19-S23
        • Gisbert J.P.
        • Pajares J.M.
        Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection: a critical review.
        Aliment Pharmacol Ther. 2004; 20: 1001-1017
        • Calvet X.
        • Gisbert J.P.
        • Suarez D.
        Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view.
        Helicobacter. 2011; 16: 346-355

      Linked Article